Zuin Marco, Cervellati Carlo, Trentini Alessandro, Passaro Angelina, Rosta Valentina, Zimetti Francesca, Zuliani Giovanni
Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.
Diagnostics (Basel). 2021 May 28;11(6):984. doi: 10.3390/diagnostics11060984.
A wealth of experimental and epidemiological evidence suggest that Apolipoprotein A-I (ApoA-I), the main protein constituent of high-density lipoprotein (HDL), may protect against Alzheimer disease (AD). To investigate this potential role, we conducted a meta-analysis of the published studies on the relationship between serum ApoA-I and AD occurrence.
We screened MEDLINE, EMBASE, Web of Science, and Scopus, for cross-sectional studies published from inception to 1 March 2021, comparing the ApoA-I serum levels between patients with AD and cognitively normal controls.
From an initial screening of 245 articles, 5 studies, including 397 AD patients (mean age 75.0 years, 234 females) and 367 controls (mean age 69.2 years, 182 females), met the inclusion criteria. Compared to healthy controls, AD subjects had a lower ApoA-I serum level. The pooled weighted mean difference from a random-effects model was -0.31 g/L ( < 0.0001) (95% Confidence Interval: [-0.62-0.01], with high heterogeneity (I = 100%). The Egger's test confirmed an absence of publication bias (t = 0.62, = 0.576).
Our study showed that AD patients present lower serum levels of ApoA-I compared to cognitively normal individuals. Further studies on large population samples are required to support this finding.
大量实验和流行病学证据表明，载脂蛋白A-I（ApoA-I）作为高密度脂蛋白（HDL）的主要蛋白质成分，可能对阿尔茨海默病（AD）具有保护作用。为了探究这一潜在作用，我们对已发表的关于血清ApoA-I与AD发生之间关系的研究进行了荟萃分析。
我们检索了MEDLINE、EMBASE、科学网和Scopus数据库，查找从数据库建立至2021年3月1日发表的横断面研究，比较AD患者与认知正常对照组的血清ApoA-I水平。
在初步筛选的245篇文章中，有5项研究符合纳入标准，包括397例AD患者（平均年龄75.0岁，女性234例）和367例对照组（平均年龄69.2岁，女性182例）。与健康对照组相比，AD患者的血清ApoA-I水平较低。随机效应模型的合并加权平均差为-0.31 g/L（<0.0001）（95%置信区间：[-0.62 - 0.01]），异质性较高（I² = 100%）。Egger检验证实不存在发表偏倚（t = 0.62，P = 0.576）。
我们的研究表明，与认知正常个体相比，AD患者的血清ApoA-I水平较低。需要对大量人群样本进行进一步研究以支持这一发现。
